Experimental CAR-T therapy targets tough cancers in small trial
NCT ID NCT06556108
First seen Jan 22, 2026 · Last updated Jun 13, 2026 · Updated 20 times
Summary
This early-stage study tested a new treatment called Anti-ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard therapies. The therapy uses a patient's own immune cells, modified to attack a protein (ALPP) found on some cancer cells. The main goals were to check safety and see if tumors shrank.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.